Functional Delivery Systems for Targeting Tumor Heterogeneity: Reversing Immunosuppression and Modulating Cancer-Immune Interplay by Di Han (618795)

“…By developing a delivery vector that specifically targets circulating malignant cells (CMCs) in patient blood samples, we established an ex vivo platform to study the dynamic interplay between patient-derived cancer cells and immune cells. …”

Functional Delivery Systems for Targeting Tumor Heterogeneity: Reversing Immunosuppression and Modulating Cancer-Immune Interplay by Di Han (618795)

“…By developing a delivery vector that specifically targets circulating malignant cells (CMCs) in patient blood samples, we established an ex vivo platform to study the dynamic interplay between patient-derived cancer cells and immune cells. …”

Hydrate-Based Gas Storage Made Greener: Methane Hydrate Formation Enhancement with a Low-Toxicity Promoter by Katipot Inkong (7979942)

“…Additionally, the effect of pressure variations (from 8 to 4 MPa at 288.2 K) was analyzed, revealing that a lower pressure decreases both the gas uptake and formation kinetics due to a reduced driving force. …”

Hydrate-Based Gas Storage Made Greener: Methane Hydrate Formation Enhancement with a Low-Toxicity Promoter by Katipot Inkong (7979942)

“…Additionally, the effect of pressure variations (from 8 to 4 MPa at 288.2 K) was analyzed, revealing that a lower pressure decreases both the gas uptake and formation kinetics due to a reduced driving force. …”

Development and Use of a Galectin-1-Specific Nanobody for Tumor Imaging and Elucidating the Role of Galectin‑1 in Cancer by Philippine Granger Joly de Boissel (21688159)

“…Galectin-1 (GAL-1) plays a crucial role in cancer biology, especially in triple-negative breast cancer (TNBC), where it facilitates immune evasion and tumor progression. …”

Hydrate-Based Gas Storage Made Greener: Methane Hydrate Formation Enhancement with a Low-Toxicity Promoter by Katipot Inkong (7979942)

“…Additionally, the effect of pressure variations (from 8 to 4 MPa at 288.2 K) was analyzed, revealing that a lower pressure decreases both the gas uptake and formation kinetics due to a reduced driving force. …”

Hydrate-Based Gas Storage Made Greener: Methane Hydrate Formation Enhancement with a Low-Toxicity Promoter by Katipot Inkong (7979942)

“…Additionally, the effect of pressure variations (from 8 to 4 MPa at 288.2 K) was analyzed, revealing that a lower pressure decreases both the gas uptake and formation kinetics due to a reduced driving force. …”

Hydrate-Based Gas Storage Made Greener: Methane Hydrate Formation Enhancement with a Low-Toxicity Promoter by Katipot Inkong (7979942)

“…Additionally, the effect of pressure variations (from 8 to 4 MPa at 288.2 K) was analyzed, revealing that a lower pressure decreases both the gas uptake and formation kinetics due to a reduced driving force. …”

Hydrate-Based Gas Storage Made Greener: Methane Hydrate Formation Enhancement with a Low-Toxicity Promoter by Katipot Inkong (7979942)

“…Additionally, the effect of pressure variations (from 8 to 4 MPa at 288.2 K) was analyzed, revealing that a lower pressure decreases both the gas uptake and formation kinetics due to a reduced driving force. …”

Correlation Plots Among TWOMBLI Outputs in (a) Combined samples, (b) AA samples, (c) C samples. by Zoë Dinkel (21402766)

Hydrate-Based Gas Storage Made Greener: Methane Hydrate Formation Enhancement with a Low-Toxicity Promoter by Katipot Inkong (7979942)

“…Additionally, the effect of pressure variations (from 8 to 4 MPa at 288.2 K) was analyzed, revealing that a lower pressure decreases both the gas uptake and formation kinetics due to a reduced driving force. …”

Hydrate-Based Gas Storage Made Greener: Methane Hydrate Formation Enhancement with a Low-Toxicity Promoter by Katipot Inkong (7979942)

“…Additionally, the effect of pressure variations (from 8 to 4 MPa at 288.2 K) was analyzed, revealing that a lower pressure decreases both the gas uptake and formation kinetics due to a reduced driving force. …”

Key safety measures including adverse events. by Anuja Dokras (8679261)

“…<div><p>Background</p><p>The risk-to-benefit ratio of using combined oral contraceptive pills (COCPs) and/or metformin for comprehensive management of polycystic ovary syndrome (PCOS) in women with obesity is unclear. As there is a lack of robust evidence on the impact of these first-line medications on cardiovascular disease (CVD) risk, we compared the effect of COCPs, metformin or both on prevalence of metabolic syndrome (MetS) in participants with hyperandrogenic PCOS and hypothesized that COCPs would increase prevalence of MetS while metformin would decrease prevalence of MetS.…”

Multi-strain model fitting based on data for influenza A and B cases from the 40th week of 2023 to the 17th week of 2024 in the United States. by Shuanglin Jing (11886368)

Comparison of phenotypes between adult control and <i>aP2-Drp1</i>^f/f mice. by Yuta Ibayashi (20404811)

Summary of KEGG enrichment analysis. by Zeynab Hosseinpoor (19762319)

“…While the expression levels of <i>IRS2</i>, <i>FOXO1</i>, and <i>ERK2</i> (<i>MAPK1</i>) were significantly decreased, the <i>SERPINF1</i> gene exhibited high expression simultaneously. pAAV-delivered <i>MIR-96</i> had no adverse effect on the viability of human RPE cells. …”

Fig 4 - by Kirralise J. Hansford (20670869)

Combined illusion score index across conditions (NI: Non-Illusion; NIT: Non-Illusion Tactile; MS: Multisensory; UV: Unimodal Visual). by Kirralise J. Hansford (20670869)

Experimental design. by Xueyan Lin (448667)

“…The escape latencies of control model gradually decreased as training time increased. Compared to controls, MHE model had significantly longer escape latencies during the 2nd, 3rd and <b>(C)</b> 4th tests (<i>p</i> < 0.001). …”

Growth of certain cancer cell lines requires IRE1 but not its enzymatic activity. by Iratxe Zuazo-Gaztelu (21071939)